Trial · NCT04931238
Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
NCT04931238, Phase 2, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19). Trials, record NCT04931238. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04931238
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
- NCT number
- NCT04931238
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- JS016
- First posted
- 2021-06-18
- Last updated
- 2021-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical status at 28 days | At 28 days from inclusion | Clinical status at 28 days assessed using a six level ordinal scale，in this scale, 1 is the minimum score and presenting a better outcome as discharge, 2 means still in-hospital but no need of oxygen therapy, 3 presents in-hospital and needing of oxygen therapy, 4 presents in-hospital needing high flow nasal oxygen therapy or non-invasive mechanical ventilation, 5 presents in-hospital needing invasive mechanical ventilation or ECMO, 6 presents death and is the worse outcome as well. |
| Secondary | All cause mortality ascertained from data analysed to day 28 | At 28 days from inclusion | All cause mortality ascertained from data analysed to day 28 |
| Secondary | Ventilator-free days within 28 days | At 28 days from inclusion | Ventilator-free days within 28 days |
| Secondary | Negative conversion rate of SARS-CoV-2 nucleic acid in on days 14 after randomization | At 14 days from inclusion | Negative conversion rate of SARS-CoV-2 nucleic acid in on days 14 after |
| Secondary | Average length of hospital stay | At 28 days from inclusion | Average length of hospital stay |
| Other | The incidence Treatment-Emergent Adverse Events of JS016 | Everyday after inclusion up to 28 days from inclusion | Incidence of Treatment-Emergent Adverse Events of JS016 includes the incidence of allergic reaction, secondary infection, liver dysfunction, acute kidney injury. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04931238
GET https://conductscience.org/api/trials/v1/NCT04931238/registered